1 / 11

Aarkstore - Hepatitis C Therapeutics

Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape. The current Hepatitis C treatment landscape consists of a combination of pegylated interferon, ribavirin and, in patients infected with genotype 1 hepatitis C, one of two direct-acting antiviral agents (DAAs). Browse full report @ http://bit.ly/1zyVhVi

JustinSterling
Download Presentation

Aarkstore - Hepatitis C Therapeutics

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Aarkstore- Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape To buy this Report Visit http://www.aarkstore.com

  2. Discounted Market Research Reports available on Aarkstore.com Offer valid till 28th February, 2015 • For more inquiries, contact at +91 9987295242 / 022-27564953 • Email: enquiry@aarkstore.com To buy this Report Visit http://www.aarkstore.com

  3. Summary Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape. The current Hepatitis C treatment landscape consists of a combination of pegylated interferon, ribavirin and, in patients infected with genotype 1 hepatitis C, one of two direct-acting antiviral agents (DAAs). Products with these mechanisms of action have performed strongly in the commercial setting, with the market leader Incivek (a DAA) having reached blockbuster sales. Browse Complete Report – http://www.aarkstore.com/healthcare/89540/hepatitis-c-therapeutics-in-major-developed-markets-to-2019

  4. Scope - A brief introduction to hepatitis C, including the disease's pathogenesis, risk factors and diagnosis, and detailed analyses of disease epidemiology and treatment algorithms.- In-depth analysis of the major antiviral drugs used in the treatment of hepatitis C, including analyses of their safety, efficacy, treatment patterns and strengths/weaknesses. Includes a heat map that compares marketed drugs in terms of safety and efficacy.- A comprehensive review of the pipeline for hepatitis C therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline is analyzed by phase distribution, molecule type and molecular target. - In-depth clinical trial enrolment, trial duration and program failure rate analyses for each molecule type and mechanism of action. Additionally, clinical trial endpoints and certain selection criteria are analyzed in great depth. This section also includes an additional heat map regarding pipeline products, and a direct cross-analysis against currently marketed products.

  5. Reasons to buy - Understand the different types of hepatitis C therapies and how treatment varies by genotype.- Understand the treatment algorithms and guidelines related to hepatitis C, how they are anticipated to change during the forecast period and where opportunities and unmet needs lie.- Understand the vast Scope of the pipeline, including which molecule types and mechanisms of action are most prominent.- Observe trends in clinical trial duration and size as clinical phase and molecule type varies. Use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for hepatitis C therapeutics.- Observe the shift in clinical trial endpoints with each clinical Phase, and use this data to potentially influence any future developmental programs. Additionally, understand the trends in enrolment by patient genotype.- Assess the potential clinical and commercial impact of current late-stage pipeline molecules and the points of opportunity which remain to be capitalized upon.

  6. Table of Contents 1.1 List of Tables1.2 List of Figures 2 Introduction2.1 Signs and Symptoms2.2 Etiology and Risk Factors2.3 Pathophysiology2.4 Epidemiology2.4.1 US and Canada2.4.2 Europe2.4.3 Japan2.4.4 Regional Prevalence of Hepatitis C Genotypes2.5 Prognosis2.6 Diagnosis and Screening2.7 Treatment2.8 Treatment Algorithms 3 Marketed Products3.1 Ribavirin3.2 Pegasys (Peginterferonalfa 2a) and PegIntron (Peginterferonalfa 2b) Hoffmann La Roche and Merck & Co

  7. List of Tables Table 1: Hepatitis C, Top Five European Countries, Disease Prevalence (%), 2011Table 2: Hepatitis C, Top Five European Markets, Most Common Risk Factors for Infection (%), 2011Table 3: Hepatitis C, Global, Estimated Distribution of Hepatitis C Genotypes (%), 2013Table 4: Market for Hepatitis C, Sources for Heat MapsTable 5: Hepatitis C Therapeutics, Global, All Pipeline Products (Discovery), 2013Table 6: Hepatitis C Therapeutics, Global, All Pipeline Products (Preclinical and IND/CTA-filed), 2013Table 7: Hepatitis C, Global, All Pipeline Products (Phase I), 2013Table 8: Hepatitis C Therapeutics, Global, All Pipeline Products (Phase II), 2013Table 9: Hepatitis C Therapeutics, Global, All Pipeline Products (Phase III), 2013Table 10: Hepatitis C Therapeutics, Global, All Pipeline Products (Undisclosed), 2013

  8. List of Figures Figure 1: Market for Hepatitis C, Global, Treatment Algorithm (Genotype 1, Triple Therapy with Incivek), 2013Figure 2: Market for Hepatitis C, Global, Treatment Algorithm (Genotype 1, Triple Therapy with Victrelis), 2013Figure 3: Market for Hepatitis C, Global, Treatment Algorithm (Genotypes 2 to 7), 2013Figure 4: Market for Hepatitis C, Global, Sales of Pegasys and PegIntron ($m), 20022012Figure 5: Market for Hepatitis C, Global, Heat Map for Marketed Products, 2013Figure 6: Market for Hepatitis C, Global, Developmental Pipeline, 2013Figure 7: Market for Hepatitis C, Global, Pipeline by Mechanism of Action and Molecule Type, 2013Figure 8: Market for Hepatitis C, Global, Clinical Trial Failure Rate by Molecule Type, 20062013Figure 9: Market for Hepatitis C, Global, Clinical Trial Failure Rates by Mechanism of Action, 20062013

  9. Related Market Research Report • Medical Document Management Systems Market by Solution (Document Scanning Software, Document Management Software), Application (Medical Records Management), Mode of Delivery (Web-Based, Cloud-Based), & by End-User (Hospitals) - Global Forecasts to 2019 • North American Laboratory Information System (LIS) Market • Europe Laboratory Information System Market • European Non-Invasive & Minimally Invasive Cardiac Output Monitoring Devices Market • Traffic Safety Market in India 2015-2019 • Patient Registry Software Market by Delivery Mode (Subscription, Ownership), Functionality (Population Health Management, Point of Care, Care Management), Database (Diabetes, Cancer, Cardiovascular, Chronic & Rare Disease) & by End User - Forecast to 2019 • Blood Coagulation Analyzer – Product Analysis • Global Equine Healthcare Market 2015-2019

  10. About Aarkstore Enterprise • Aarkstore Enterprise provides Industry and Market Analysis and Research Report with expertise and technology knowledge on business improvement and market acquisition. • Aarkstore achieved its debut pad in the year 2008 to explore, work on assignments and cater worldwide clients and business giants with business research on trends, markets and technologies. The latest set of applications guarantees active analysis and Market Research understanding for budding enterpriser and consultants to relate industry ground research.

  11. Contact Us Office Office No. - 809, 8th Floor,B-Wing, Mahaavir Icon, Plot No.- 89 & 90, Sector-15,CBD-Belapur, Navi Mumbai – 400614, Maharashtra, India. Telefax No: +91 22 4127 6660 24/7 Online Support: +91 9987295242 General Inquiries : +91 - 22 2756 4953 You Can Visit http://www.aarkstore.com OR Mail us at contact@aarkstore.com Blog : http://www.aarkstore.com/blog/ Conference : http://conference.aarkstore.com/ News : http://www.aarkstore.com/news

More Related